Trial Profile
A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary) ; SRA 515 (Primary)
- Indications Ewing's sarcoma; Malignant fibrous histiocytoma; Neurofibrosarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2024 Planned End Date changed from 15 Jan 2030 to 15 Jun 2030.
- 05 Jan 2024 Planned primary completion date changed from 15 Jan 2029 to 15 Jun 2029.
- 05 Jan 2024 Planned initiation date changed from 15 Jan 2024 to 15 Jun 2024.